Mar 29, 2022 5:00 pm EDT Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
Mar 25, 2022 7:00 am EDT Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
Mar 11, 2022 7:00 am EST Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
Feb 14, 2022 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
Feb 7, 2022 7:00 am EST Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 3, 2022 7:00 am EST Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
